Usefulness of repeated N-terminal pro-B-type natriuretic peptide measurements as incremental predictor for long-term cardiovascular outcome after vascular surgery.

Plasma N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) levels improve preoperative cardiac risk stratification in vascular surgery patients. However, single preoperative measurements of NT-pro-BNP cannot take into account the hemodynamic stress caused by anesthesia and surgery. Therefore, the aim of the present study was to assess the incremental predictive value of changes in NT-pro-BNP during the perioperative period for long-term cardiac mortality. Detailed cardiac histories, rest left ventricular echocardiography, and NT-pro-BNP levels were obtained in 144 patients before vascular surgery and before discharge. The study end point was the occurrence of cardiovascular death during a median follow-up period of 13 months (interquartile range 5 to 20). Preoperatively, the median NT-pro-BNP level in the study population was 314 pg/ml (interquartile range 136 to 1,351), which increased to a median level of 1,505 pg/ml (interquartile range 404 to 6,453) before discharge. During the follow-up period, 29 patients (20%) died, 27 (93%) from cardiovascular causes. The median difference in NT-pro-BNP in the survivors was 665 pg/ml, compared to 5,336 pg/ml in the patients who died (p = 0.01). Multivariate Cox regression analyses, adjusted for cardiac history and cardiovascular risk factors (age, angina pectoris, myocardial infarction, stroke, diabetes mellitus, renal dysfunction, body mass index, type of surgery and the left ventricular ejection fraction), demonstrated that the difference in NT-pro-BNP level between pre- and postoperative measurement was the strongest independent predictor of cardiac outcome (hazard ratio 3.06, 95% confidence interval 1.36 to 6.91). In conclusion, the change in NT-pro-BNP, indicated by repeated measurements before surgery and before discharge is the strongest predictor of cardiac outcomes in patients who undergo vascular surgery.

[1]  Perioperative cardiac morbidity , 1990, Anesthesiology.

[2]  M. Cheitlin,et al.  BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial , 2010 .

[3]  Jeroen J. Bax,et al.  Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery , 2005, Heart.

[4]  Y. Pinto,et al.  Amino-terminal pro-B-type natriuretic peptide testing in renal disease. , 2008, The American journal of cardiology.

[5]  L. Køber,et al.  N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease , 2005 .

[6]  Jeroen J. Bax,et al.  Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery , 2009 .

[7]  H. White,et al.  N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes , 2004, Circulation.

[8]  Jeroen J. Bax,et al.  Predictors of cardiac events after major vascular surgery: Role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. , 2001, JAMA.

[9]  Jeroen J. Bax,et al.  Plasma N-terminal pro-B-type natriuretic peptide as a predictor of perioperative and long-term outcome after vascular surgery. , 2009, Journal of vascular surgery.

[10]  Jeroen J. Bax,et al.  Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery , 2005, Heart.

[11]  Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. , 2005 .

[12]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[13]  Malte Kelm,et al.  Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. , 2009, European heart journal.

[14]  O. Nielsen,et al.  Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study. , 2008, American heart journal.

[15]  Jeroen J. Bax,et al.  Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass. , 2006, The American journal of cardiology.

[16]  H. Yeh,et al.  Preoperative plasma N‐terminal pro‐brain natriuretic peptide as a marker of cardiac risk in patients undergoing elective non‐cardiac surgery , 2005, The British journal of surgery.

[17]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[18]  Jeroen J. Bax,et al.  Influence of renal function on the usefulness of N-terminal pro-B-type natriuretic peptide as a prognostic cardiac risk marker in patients undergoing noncardiac vascular surgery. , 2008, The American journal of cardiology.

[19]  B. Biccard,et al.  A meta‐analysis of the utility of pre‐operative brain natriuretic peptide in predicting early and intermediate‐term mortality and major adverse cardiac events in vascular surgical patients , 2008, Anaesthesia.

[20]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[21]  Jeroen J. Bax,et al.  Predictors of Cardiac Events After Major Vascular Surgery Role of Clinical Characteristics, Dobutamine Echocardiography, and b-Blocker Therapy , 2001 .

[22]  S. Yusuf,et al.  Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. , 2009, Journal of the American College of Cardiology.

[23]  J. Dernellis,et al.  Assessment of cardiac risk before non-cardiac surgery: brain natriuretic peptide in 1590 patients , 2006, Heart.

[24]  J. Cleland,et al.  Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. , 2003, American heart journal.

[25]  Charles Weissman,et al.  Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. , 2003, Journal of the American College of Cardiology.

[26]  Alan S Maisel,et al.  How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. , 2006, American heart journal.

[27]  H. T. Lee.  N-Terminal Pro-brain Natriuretic Peptide Identifies Patients at High Risk for Adverse Cardiac Outcome after Vascular Surgery , 2008 .

[28]  Saurabh Kumar,et al.  Prognostic Value of Brain Natriuretic Peptide in Noncardiac Surgery: A Meta-analysis , 2009, Anesthesiology.

[29]  H. Itoh,et al.  Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. , 1995, Circulation.

[30]  M. Sabatine,et al.  Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. , 2004, Journal of the American College of Cardiology.

[31]  J. D. de Lemos,et al.  Amino-terminal pro-B-type natriuretic peptides: testing in general populations. , 2008, The American journal of cardiology.

[32]  C. Frampton,et al.  NTproBNP‐guided drug treatment for chronic heart failure: design and methods in the “BATTLESCARRED” trial , 2006, European journal of heart failure.

[33]  E F Cook,et al.  Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. , 1999, Circulation.